Er-Kim to Distribute Nulibry® and Zokinvy® in EMEA and Eurasian Markets
Thursday, September 25, 2025
Er-Kim, an international pharmaceutical company focused on commercialising novel therapies in the EMEA region, has signed an agreement with Sentynl Therapeutics, Inc. to distribute Nulibry® (fosdenopterin) and Zokinvy® (lonafarnib). Both therapies are the only EMA and FDA-approved treatments for their respective conditions, and the collaboration will provide patients in Central and Eastern Europe, the Mediterranean, and Eurasian markets with access to these medicines.
Nulibry is approved for the treatment of molybdenum cofactor deficiency (MoCD) Type A, a rare, life-threatening genetic disorder that can cause severe neurological damage and often appears at birth. Without treatment, the disease progresses rapidly and may lead to early death in children.
Zokinvy is approved for Hutchinson-Gilford Progeria Syndrome (HGPS) and certain Progeroid Laminopathies (PDPL) in patients aged 12 months and older with a body surface area of 0.39 m² or more. These conditions cause rapid premature ageing and cardiovascular problems due to the accumulation of harmful proteins, resulting in a much faster ageing process compared with healthy individuals.
Under the agreement, Er-Kim will distribute Nulibry and Zokinvy across 33 countries, including Poland, Greece, Turkey, Czechia, Romania, Kazakhstan, and Russia. The partnership aims to expand patient access to these rare disease treatments across a broad geographic area, aligning care with standards available in the U.S. and Western Europe.
Source: globenewswire.com
